• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Nektar Therapeutics - Articles and news items

collabs

Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers’ Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +